An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer

Trial Profile

An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Apalutamide (Primary)
  • Indications Prostate cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Aragon Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Feb 2017 Results of a sub group analysis from Phase II portion (n=46) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 27 Jan 2016 Planned end date changed from 1 Dec 2015 to 1 Dec 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top